8CF2
 
 | | Solution structure of the RNA helix formed by the 5'-end of U1 snRNA and an A-1 bulged 5'-splice site in complex with SMN-CY | | Descriptor: | 4-[(3~{S})-3-ethylpiperazin-1-yl]-2-fluoranyl-~{N}-(2-methylimidazo[1,2-a]pyrazin-6-yl)benzamide, RNA (5'-R(P*AP*UP*AP*CP*(PSU)P*(PSU)P*AP*CP*CP*UP*G)-3'), RNA (5'-R(P*GP*GP*AP*GP*UP*AP*AP*GP*UP*CP*U)-3') | | Authors: | Malard, F, Marquevielle, J, Campagne, S. | | Deposit date: | 2023-02-02 | | Release date: | 2024-02-21 | | Last modified: | 2024-05-22 | | Method: | SOLUTION NMR | | Cite: | The diversity of splicing modifiers acting on A-1 bulged 5'-splice sites reveals rules for rational drug design.
Nucleic Acids Res., 52, 2024
|
|
8R8P
 | |
8R62
 | | Solution structure of Risdiplam bound to the RNA duplex formed upon 5'-splice site recognition | | Descriptor: | 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-1~{H}-pyrido[1,2-a]pyrimidin-4-one, RNA (5'-R(*AP*UP*AP*CP*(PSU)P*(PSU)P*AP*CP*CP*UP*G)-3'), RNA (5'-R(P*GP*GP*AP*GP*UP*AP*AP*GP*UP*CP*U)-3') | | Authors: | Malard, F, Campagne, S. | | Deposit date: | 2023-11-20 | | Release date: | 2024-03-06 | | Last modified: | 2024-05-22 | | Method: | SOLUTION NMR | | Cite: | The diversity of splicing modifiers acting on A-1 bulged 5'-splice sites reveals rules for rational drug design.
Nucleic Acids Res., 52, 2024
|
|
8R63
 | | Solution structure of branaplam bound to the RNA duplex formed upon 5'-splice site recognition | | Descriptor: | 5-(1~{H}-pyrazol-4-yl)-2-[6-(2,2,6,6-tetramethylpiperidin-4-yl)oxypyridazin-3-yl]phenol, RNA (5'-R(*AP*UP*AP*CP*(PSU)P*(PSU)P*AP*CP*CP*UP*G)-3'), RNA (5'-R(P*GP*GP*AP*GP*UP*AP*AP*GP*UP*CP*U)-3') | | Authors: | Malard, F, Campagne, S. | | Deposit date: | 2023-11-20 | | Release date: | 2024-03-06 | | Last modified: | 2024-05-22 | | Method: | SOLUTION NMR | | Cite: | The diversity of splicing modifiers acting on A-1 bulged 5'-splice sites reveals rules for rational drug design.
Nucleic Acids Res., 52, 2024
|
|
